$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000121390024109524 Filed on December 17, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue			$3.453M
YoY Change			76.86%
Cost Of Revenue			$2.373M
YoY Change			58.65%
Gross Profit			$1.080M
YoY Change			136.5%
Gross Profit Margin			31.27%
Selling, General & Admin			$7.902M
YoY Change			14.08%
% of Gross Profit			731.86%
Research & Development			$5.065M
YoY Change			-27.02%
% of Gross Profit			469.14%
Depreciation & Amortization			$224.5K
YoY Change			12.65%
% of Gross Profit			20.79%
Operating Expenses			$12.97M
YoY Change			-6.49%
Operating Profit			-$11.89M
YoY Change			-0.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net			$125.2K
YoY Change			30.72%
Pretax Income			-$12.32M
YoY Change			3.87%
Income Tax
% Of Pretax Income
Net Earnings			-$12.32M
YoY Change			3.87%
Net Earnings / Revenue			-356.74%
Basic Earnings Per Share			-$0.46
Diluted Earnings Per Share			-$0.46
COMMON SHARES
Basic Shares Outstanding	30.84M shares	30.81M shares	26.76M shares
Diluted Shares Outstanding			26.76M shares

Balance Sheet

Concept	2024 Q4	2024 Q3	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$1.460M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$2.635M
Prepaid Expenses
Receivables		$176.6K
Other Receivables
Total Short-Term Assets		$4.631M
YoY Change		-36.67%
LONG-TERM ASSETS
Property, Plant & Equipment		$416.8K
YoY Change		-20.72%
Goodwill
YoY Change
Intangibles		$67.26K
YoY Change		-24.91%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$739.0K
YoY Change		-5.78%
TOTAL ASSETS
Total Short-Term Assets		$4.631M
Total Long-Term Assets		$739.0K
Total Assets		$5.370M
YoY Change		-33.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.029M
YoY Change		50.23%
Accrued Expenses		$1.184M
YoY Change		6.91%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.213M
YoY Change		23.46%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.213M
Total Long-Term Liabilities
Total Liabilities		$4.548M
YoY Change		146.11%
SHAREHOLDERS EQUITY
Retained Earnings		-$75.00M
YoY Change		19.64%
Common Stock		$30.82K
YoY Change		28.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$822.0K
YoY Change
Total Liabilities & Shareholders Equity		$5.370M
YoY Change		-33.68%

Cashflow Statement

Concept	2024 Q4	2024 Q3	2024
OPERATING ACTIVITIES
Net Income			-$12.32M
YoY Change			3.87%
Depreciation, Depletion And Amortization			$224.5K
YoY Change			12.65%
Cash From Operating Activities			-$11.01M
YoY Change			-14.55%
INVESTING ACTIVITIES
Capital Expenditures			$120.2K
YoY Change			-68.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$120.2K
YoY Change			-104.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.034M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$7.270M
YoY Change			-1.75%
NET CHANGE
Cash From Operating Activities			-$11.01M
Cash From Investing Activities			-$120.2K
Cash From Financing Activities			$7.270M
Net Change In Cash			-$3.862M
YoY Change			36.11%
FREE CASH FLOW
Cash From Operating Activities			-$11.01M
Capital Expenditures			$120.2K
Free Cash Flow			-$11.13M
YoY Change			-16.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-40439
CY2024	dei	Entity Registrant Name EntityRegistrantName	NeuroOne Medical Technologies Corporation
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Dr.
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2024	dei	City Area Code CityAreaCode	952
CY2024	dei	Local Phone Number LocalPhoneNumber	426-1383
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2024	dei	Trading Symbol TradingSymbol	NMTC
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	30300000	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30841830	shares
CY2024	dei	Auditor Firm AuditorFirmId	23
CY2024	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1460042	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5322493	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	176636	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	2635153	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	142633	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216461	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263746	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	4630925	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7312925	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	67262	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	254910	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	416843	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024Q3	us-gaap	Assets Assets	5369940	usd
CY2023Q3	us-gaap	Assets Assets	8097314	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1029206	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	685104	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1184014	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2213220	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1792626	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2140315	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	194392	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55284	usd
CY2024Q3	us-gaap	Liabilities Liabilities	4547927	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1847910	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30816499	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30816499	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23928945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23928945	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	30816	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	23929	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75795610	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68911778	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75004413	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62686303	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	822013	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5369940	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8097314	usd
CY2024	us-gaap	Revenues Revenues	3453003	usd
CY2023	us-gaap	Revenues Revenues	1952441	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	2373336	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1495924	usd
CY2024	us-gaap	Gross Profit GrossProfit	1079667	usd
CY2023	us-gaap	Gross Profit GrossProfit	456517	usd
CY2023	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7901695	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6926269	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5065181	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6940686	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	12966876	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13866955	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-11887209	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11955250	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327092	usd
CY2024	nmtc	Financing Costs FinancingCosts	228988	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	125179	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	95759	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12318110	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11859491	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-12318110	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26762392	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26762392	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18121108	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18121108	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6037500	usd
CY2023	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	2552656	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1071663	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1105457	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	119419	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2024	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With2024 Private Placement StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWith2024PrivatePlacement	836777	usd
CY2024	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	5033906	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	296161	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1344476	usd
CY2024	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	81403	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	53124	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-12318110	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	822013	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-12318110	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	246791	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	199266	usd
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	101329	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1344476	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1105457	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327092	usd
CY2024	nmtc	Private Placement Warrant Issuance Costs Reclassed To Financing Activities PrivatePlacementWarrantIssuanceCostsReclassedToFinancingActivities	127659	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-32143	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	45571	usd
CY2024	nmtc	Noncash Lease Expense NoncashLeaseExpense	-113534	usd
CY2023	nmtc	Noncash Lease Expense NoncashLeaseExpense	-109832	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	176636	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33237	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	908467	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1022148	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-47285	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-32903	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	66993	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-247189	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	16214	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1225313	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11011840	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12886874	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	4500000	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	7500	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120197	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	384117	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120197	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2649964	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	836777	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	6037500	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1813223	usd
CY2024	nmtc	Proceeds From Issuance Of Common Stock In Connection With Atthemarket Offering Program ProceedsFromIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	5033906	usd
CY2023	nmtc	Proceeds From Issuance Of Common Stock In Connection With Atthemarket Offering Program ProceedsFromIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	2552656	usd
CY2024	nmtc	Paymentof Issuance Costs Attributed To Common Stock And Warrants Issued In Private Placement PaymentofIssuanceCostsAttributedToCommonStockAndWarrantsIssuedInPrivatePlacement	1320	usd
CY2023	nmtc	Paymentof Issuance Costs Attributed To Common Stock And Warrants Issued In Private Placement PaymentofIssuanceCostsAttributedToCommonStockAndWarrantsIssuedInPrivatePlacement	836938	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	236597	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	234725	usd
CY2024	nmtc	Paymentof Deferred Issuance Costs In Connection With Atthemarket Offering Program PaymentofDeferredIssuanceCostsInConnectionWithAtthemarketOfferingProgram	20000	usd
CY2024	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	75000	usd
CY2024	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	81403	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	119419	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7269586	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7399074	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3862451	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2837836	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5322493	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8160329	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1460042	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5322493	usd
CY2023	nmtc	Unpaid Purchases Of Property And Equipment UnpaidPurchasesOfPropertyAndEquipment	4631	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199385	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2024	nmtc	Noncash Warrants Issued In Connection With Debt Facility NoncashWarrantsIssuedInConnectionWithDebtFacility	53124	usd
CY2024	nmtc	Unpaid Issuance Costs In Connection With Private Placement UnpaidIssuanceCostsInConnectionWithPrivatePlacement	185903	usd
CY2024	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets	95837	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75000000	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts presented in the prior year period have been reclassified to conform to current period financial statement presentation. The financing proceeds and issuance costs attributed to the at-the-market offering program and private placement reflected in the statements of cash flows during the comparable prior year period were reclassified into two separate line item categories.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2140315	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2140315	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1813223	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327092	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2140315	usd
CY2024Q3	us-gaap	Advertising Expense AdvertisingExpense	108993	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	173430	usd
CY2024	nmtc	Number Of Days To Remedy Default NumberOfDaysToRemedyDefault	P90D
CY2024	us-gaap	Royalty Expense RoyaltyExpense	150000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	150000	usd
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	us-gaap	Operating Leases Rent Expense Contingent Rentals OperatingLeasesRentExpenseContingentRentals	4241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	138917	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	134632	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199385	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	254910	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	260160	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184400	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2024Q3	nmtc	Lessee Operating Lease Liability To Be Paid Remainder Of Calendar Year LesseeOperatingLeaseLiabilityToBePaidRemainderOfCalendarYear	35122	usd
CY2024Q3	nmtc	Lessee Operating Lease Liability Payments Due Fiscal Year LesseeOperatingLeaseLiabilityPaymentsDueFiscalYear	66097	usd
CY2024Q3	nmtc	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	78945	usd
CY2024Q3	nmtc	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	81708	usd
CY2024Q3	nmtc	Lessee Operating Lease Liability Payments Due Four Year LesseeOperatingLeaseLiabilityPaymentsDueFourYear	34815	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	296687	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	36527	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	260160	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65768	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	194392	usd
CY2024Q3	us-gaap	Inventory Gross InventoryGross	877065	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	1202778	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	192360	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	343597	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1565728	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180311	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	2635153	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	102318	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22315	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22315	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	67262	usd
CY2024Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	976303	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860737	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	976303	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	860737	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	559460	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	334984	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	416843	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024	us-gaap	Depreciation Depreciation	224476	usd
CY2023	us-gaap	Depreciation Depreciation	176951	usd
CY2023Q3	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	39643	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7500	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	950260	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	874382	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65768	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129116	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	108036	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	104024	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	59950	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1184014	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2020	us-gaap	Payments For Fees PaymentsForFees	2000000	usd
CY2022Q3	nmtc	Payment To The Company PaymentToTheCompany	3500000	usd
CY2024	nmtc	Transaction Price Associated With The Development Agreement TransactionPriceAssociatedWithTheDevelopmentAgreement	5400000	usd
CY2024	nmtc	Fair Value Adjustment To The Transaction Price Of The Development Agreement And Amendment FairValueAdjustmentToTheTransactionPriceOfTheDevelopmentAgreementAndAmendment	100000	usd
CY2023	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1455188	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1455188	usd
CY2024	us-gaap	Revenues Revenues	3453003	usd
CY2023	us-gaap	Revenues Revenues	1952441	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1344476	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1105457	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1239915	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.4
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89295	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	469512	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.55
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.78
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1708427	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20064	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1225669	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.26
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	120000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.33
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814096	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	22685	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2814096	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	22685	usd
CY2024Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumber	1409840	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.79
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	22643	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0.99
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0.89
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.119	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.574	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.046	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2944446	shares
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.001
CY2024Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2208333	shares
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.9
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2024Q3	nmtc	Gross Proceeds GrossProceeds	2650000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.19
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1813223	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327092	usd
CY2022Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	14500000	usd
CY2022Q4	nmtc	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.03	pure
CY2023Q3	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	2600000	usd
CY2023Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	4800000	usd
CY2024Q1	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	9300000	usd
CY2024Q3	nmtc	Amount Of Common Stock Of Sales Agreement AmountOfCommonStockOfSalesAgreement	3000000	usd
CY2024	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3748913	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1439677	shares
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5033906	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2552656	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	5250000	shares
CY2023Q3	nmtc	Warrant To Purchase Shares Of Common Stock WarrantToPurchaseSharesOfCommonStock	787500	shares
CY2023Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5200000	usd
CY2024	nmtc	Exercise Price Of Warrants Issued ExercisePriceOfWarrantsIssued	0.66
CY2024	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2024	nmtc	Debt Financing As Issuance Cost DebtFinancingAsIssuanceCost	50000	shares
CY2024Q3	us-gaap	Securities Borrowed SecuritiesBorrowed	500000	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5000000	usd
CY2024	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	202656	usd
CY2024	us-gaap	Legal Fees LegalFees	74532	usd
CY2024	nmtc	Noncash Warrants Issued In Connection With Debt Facility NoncashWarrantsIssuedInConnectionWithDebtFacility	53124	usd
CY2024	nmtc	Transaction Fee Amount TransactionFeeAmount	75000	usd
CY2024Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	101329	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.024	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.017	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.019	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.292	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.296	pure
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	13789594	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	11657158	usd
CY2024Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	30258	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	28352	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	97803	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	63301	usd
CY2024Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2650371	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1780649	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1609718	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1314487	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	986952	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	788790	usd
CY2024Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	19164696	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15632737	usd
CY2024Q4	nmtc	Deferred Tax Liabilities Fixed Asset And Other DeferredTaxLiabilitiesFixedAssetAndOther	136659	usd
CY2023Q4	nmtc	Deferred Tax Liabilities Fixed Asset And Other DeferredTaxLiabilitiesFixedAssetAndOther	204829	usd
CY2024Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	136659	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	204829	usd
CY2024Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19028037	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15427908	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19165000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15633000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	19028000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15428000	usd
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47958000	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40571000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	231968	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	52100	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	231968	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	284068	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	231968	usd
CY2024	nmtc	Unrecognized Tax Position UnrecognizedTaxPosition	P12M
CY2024Q3	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	1	pure
CY2024	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1	pure
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.03	pure
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	nmtc	Financing Costs FinancingCosts		usd
CY2023	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2024	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	nmtc	Private Placement Warrant Issuance Costs Reclassed To Financing Activities PrivatePlacementWarrantIssuanceCostsReclassedToFinancingActivities		usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2024	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
CY2024	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2024	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments		usd
CY2024	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	nmtc	Paymentof Deferred Issuance Costs In Connection With Atthemarket Offering Program PaymentofDeferredIssuanceCostsInConnectionWithAtthemarketOfferingProgram		usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2024	nmtc	Unpaid Purchases Of Property And Equipment UnpaidPurchasesOfPropertyAndEquipment		usd
CY2023	nmtc	Noncash Warrants Issued In Connection With Debt Facility NoncashWarrantsIssuedInConnectionWithDebtFacility		usd
CY2023	nmtc	Unpaid Issuance Costs In Connection With Private Placement UnpaidIssuanceCostsInConnectionWithPrivatePlacement		usd
CY2023	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets		usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableCurrent
CY2023Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableCurrent
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2024	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2024	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2024Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
0001213900-24-109524-index-headers.html	Edgar Link	pending
0001213900-24-109524-index.html	Edgar Link	pending
0001213900-24-109524.txt	Edgar Link	pending
0001213900-24-109524-xbrl.zip	Edgar Link	pending
ea0224514-10k_neuroon.htm	Edgar Link	pending
ea022451401ex10-9_neuroone.htm	Edgar Link	pending
ea022451401ex19-1_neuroone.htm	Edgar Link	pending
ea022451401ex21-1_neuroone.htm	Edgar Link	pending
ea022451401ex23-1_neuroone.htm	Edgar Link	pending
ea022451401ex31-1_neuroone.htm	Edgar Link	pending
ea022451401ex31-2_neuroone.htm	Edgar Link	pending
ea0224514-10k_neuroon_htm.xml	Edgar Link	completed
ea022451401ex32-1_neuroone.htm	Edgar Link	pending
ea022451401ex32-2_neuroone.htm	Edgar Link	pending
ea022451401ex97-1_neuroone.htm	Edgar Link	pending
ex19-1_001.jpg	Edgar Link	pending
ex97-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20240930_cal.xml	Edgar Link	unprocessable
nmtc-20240930_pre.xml	Edgar Link	unprocessable
nmtc-20240930_lab.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmtc-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q4 Form 10-K Financial Statement

#000121390024109524 Filed on December 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q4 Form 10-K Financial Statement

#000121390024109524 Filed on December 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc